All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-06-17T10:11:20.000Z

What factors impact response to mesenchymal stromal cells in patients with acute GvHD?

During the 25th Congress of the European Hematology Association (EHA), the GvHD Hub spoke to Antonio Galleu, King's College London, London, UK. We asked: What factors impact response to mesenchymal stromal cells in patients with acute GvHD?

Influencing factors include prognostic markers identified prior to infusion, characteristic molecular changes observed during or following mesenchymal stromal cell treatment, or characteristics of the treatment itself. Here, Antonio Galleu discusses the key determinants of patient outcome to mesenchymal stromal cell infusion.

What factors impact response to mesenchymal stromal cells in patients with acute GvHD?

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox